157 related articles for article (PubMed ID: 11750253)
21. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
[TBL] [Abstract][Full Text] [Related]
22. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Resnick MI; Roehrborn CG
Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
24. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Wyllie MG
BJU Int; 2003 Dec; 92(9):1044; author reply 1044-5. PubMed ID: 14632873
[No Abstract] [Full Text] [Related]
26. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
[TBL] [Abstract][Full Text] [Related]
27. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
[TBL] [Abstract][Full Text] [Related]
28. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
[TBL] [Abstract][Full Text] [Related]
29. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Buzelin JM; Hebert M; Blondin P
Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
[TBL] [Abstract][Full Text] [Related]
30. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial.
Lapitan MC; Acepcion V; Mangubat J
J Int Med Res; 2005; 33(5):562-73. PubMed ID: 16222890
[TBL] [Abstract][Full Text] [Related]
31. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
[TBL] [Abstract][Full Text] [Related]
32. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
Mazo EB; Matushevskiĭ IA; Nikitin IuIu
Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
[TBL] [Abstract][Full Text] [Related]
33. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
35. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
[TBL] [Abstract][Full Text] [Related]
36. Alfuzosin for the management of benign prostate hyperplasia.
Weiner DM; Lowe FC
Expert Opin Pharmacother; 2003 Nov; 4(11):2057-63. PubMed ID: 14596659
[TBL] [Abstract][Full Text] [Related]
37. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
McVary KT
J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
[TBL] [Abstract][Full Text] [Related]
38. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
[TBL] [Abstract][Full Text] [Related]
40. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
Tkachuk VN; Kuz'min IV
Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
